Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumours: A 102-case retrospective study

#4346

Introduction: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumours (TNETs).

Aim(s): This study aimed to evaluate the efficacy and safety of surufatinib in well-differentiated TNETs by conducting a single centre retrospective analysis.

Materials and methods: We conducted a retrospective study at Fudan University Shanghai Cancer Center, including 102 patients with low to middle grade TNETs. This study assessed the efficacy and safety of surufatinib in this population.

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: neuroendocrine tumour, thymic, surufatinib, treatment,